Aeglea Biotherapeutics (AGLE) was Downgraded to a Hold Rating at H.C. Wainwright

In a report released today, Edward White from H.C. Wainwright downgraded Aeglea Biotherapeutics (AGLEResearch Report) to Hold, with a price target of $1.00. The company’s shares closed last Thursday at $0.89.

According to, White is ranked 0 out of 5 stars with an average return of -29.8% and a 19.9% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

Aeglea Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $7.57, a 722.8% upside from current levels. In a report released today, Piper Sandler also downgraded the stock to Hold with a $1.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $8.50 and a one-year low of $1.29. Currently, Aeglea Biotherapeutics has an average volume of 596.7K.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGLE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Read More on AGLE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More